J. Romero

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

T. Clackson, R. Anjum, V. Rivera, 2016, Journal of medicinal chemistry.

Rational design of a new antibiotic class for drug-resistant infections

S. McLeod, A. Ferguson, G. Drusano, 2021, Nature.

In-silico guided discovery of novel CCR9 antagonists

Jing Zhang, Katie Hall, Yuchuan Wu, 2018, Journal of Computer-Aided Molecular Design.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2010, Journal of medicinal chemistry.

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

S. McLeod, R. Tommasi, M. Sacco, 2020, Journal of medicinal chemistry.

Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease.

Jing Zhang, Jan Romero, Sabrina Stucka, 2015, Bioorganic & medicinal chemistry letters.

Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease.

J. Cross, M. Varoglu, B. Lippa, 2015, Bioorganic & medicinal chemistry letters.

Discovery of indole inhibitors of chemokine receptor 9 (CCR9).

Bhaumik A. Pandya, M. Varoglu, B. Lippa, 2016, Bioorganic & medicinal chemistry letters.

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2011, Bioorganic & medicinal chemistry letters.